+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Recordati SpA (REC) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 64 Pages
  • September 2026
  • GlobalData
  • ID: 4278646
Recordati SpA (REC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recordati SpA (Recordati), a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures, and markets pharmaceuticals. The company offers pharmaceuticals for conditions related to cardiovascular, urology and uro-oncology, gastroenterological, cough and cold, metabolic, endocrinology, oncology and the central nervous system, among others. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives, and others. It also manufactures active pharmaceutical ingredients (APIs) and intermediates. The company sells its products directly in the countries of its operations and through licensees in other countries. Recordati is headquartered in Milan, Italy.

Recordati SpA Key Recent Developments

  • Aug 31, 2026: BioGaia and Recordati strengthen their partnership in Spain and Portugal
  • Jul 31, 2026: Interim Report First Half (as at 30 June 2026)
  • Jul 30, 2026: Recordati: Publication of the Interim Report First Half (As at 30.06.2026)
  • Jul 29, 2026: Recordati: Solid Momentum of the Group Continues First Half 2026. Net Revenue +6.6%, EBITDA +8.8%, Adjusted Net Income +6.7%

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Recordati SpA - Key Facts
  • Recordati SpA - Key Employees
  • Recordati SpA - Key Employee Biographies
  • Recordati SpA - Major Products and Services
  • Recordati SpA - History
  • Recordati SpA - Company Statement
  • Recordati SpA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Recordati SpA - Business Description
  • Business Segment: Rare Diseases
  • Overview
  • Performance
  • Business Segment: Specialty and Primary Care
  • Overview
  • Performance
  • Geographical Segment: Africa
  • Performance
  • Geographical Segment: America
  • Performance
  • Geographical Segment: Asia and Oceania
  • Performance
  • Geographical Segment: Europe
  • Performance
  • R&D Overview
  • Recordati SpA - Corporate Strategy
  • Recordati SpA - SWOT Analysis
  • SWOT Analysis - Overview
  • Recordati SpA - Strengths
  • Recordati SpA - Weaknesses
  • Recordati SpA - Opportunities
  • Recordati SpA - Threats
  • Recordati SpA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Recordati SpA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 31, 2026: BioGaia and Recordati strengthen their partnership in Spain and Portugal
  • Jul 31, 2026: Interim Report First Half (as at 30 June 2026)
  • Jul 30, 2026: Recordati: Publication of the Interim Report First Half (As at 30.06.2026)
  • Jul 29, 2026: Recordati: Solid Momentum of the Group Continues First Half 2026. Net Revenue +6.6%, EBITDA +8.8%, Adjusted Net Income +6.7%
  • Jun 26, 2026: Ionis grants Recordati rights to zilganersen for Alexander disease
  • May 12, 2026: Recordati Reports Continued Group Growth in Q1 2026; Net Revenues +4.9%, EBITDA +5.0%, Adjusted Net Income +7.2%
  • May 12, 2026: Recordati First Quarter 2026 Results
  • Feb 17, 2026: RECORDATI Announces Preliminary 2025 Financial Results: Revenues +11.8%, EBITDA +14.5%, Adjusted Net Income +14.5%
  • Feb 17, 2026: Recordati Reports Preliminary Full-Year 2025 Results: Revenue +11.8%, EBITDA +14.5%, Adjusted Net Income +14.5%
  • Oct 23, 2025: Recordati Appoints Mike McClellan As New Chief Financial Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • Recordati SpA, Key Facts
  • Recordati SpA, Key Employees
  • Recordati SpA, Key Employee Biographies
  • Recordati SpA, Major Products and Services
  • Recordati SpA, History
  • Recordati SpA, Subsidiaries
  • Recordati SpA, Key Competitors
  • Recordati SpA, Ratios based on current share price
  • Recordati SpA, Annual Ratios
  • Recordati SpA, Interim Ratios
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Recordati SpA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Recordati SpA, Performance Chart (2021 - 2025)
  • Recordati SpA, Ratio Charts
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Recordati SpA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Zambon Co SpA
  • Chiesi Farmaceutici SpA
  • UCB SA
  • Ipsen SA
  • Les Laboratoires Servier SAS